RBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1

RBC Capital analyst Luca Issi has downgraded Caribou Biosciences (NASDAQ: CRBU) from Outperform to Sector Perform. The price target for the stock has been significantly reduced from $10 to $1.